VIDEO: Breast cancer researcher discusses findings from I-SPY2 trial
Click Here to Manage Email Alerts
CHICAGO — Three abstracts on results from the I-SPY2 trial to evaluate pathological complete response following neoadjuvant breast cancer treatments were presented at ASCO Annual Meeting.
Angela DeMichele, MD, co-leader of the Breast Cancer Research Program at Penn Medicine and an author of all three abstracts, spoke with Healio about the I-SPY2 trial and the main takeaways from each abstract.
“These abstracts are actually very unique because they represent all of the patients who have enrolled in the I-SPY trial to date, with the analyses separated out into triple-negative, HER2-positive and hormone receptor-positive [patients],” DeMichele said.
She added that “we’ve recently done this analysis looking at the over 1,000 patients who’ve been treated on the trial to see what we can learn not just about individual treatments, but about the overarching biology and natural history of these different types of breast cancer.”
DeMichele explained that patients included in the trial had high-risk breast cancer indicated by tumor size and MammaPrint results.
She noted that by assessing neoadjuvant treatment in high-risk patients by subtype, “we’ve learned some really important things about breast cancer and how it responds to therapy.”
References:
- Cha J, et al. Abstract 592. Presented at: ASCO Annual Meeting; June 3-7, 2022.
- Thomas A, et al. Abstract 510. Presented at: ASCO Annual Meeting; June 3-7, 2022.
- Ye D, et al. Abstract 591. Presented at: ASCO Annual Meeting; June 3-7, 2022.
Collapse
Click Here to Manage Email Alerts